Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism

Crizotinib is a standard treatment for advanced ALK‐positive non‐small‐cell lung cancer (NSCLC). We undertook this study to investigate the pharmacokinetics of crizotinib and clinical and pharmacogenomic factors that may increase the risk of adverse events (AEs). We defined clinically significant AE...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Sci
Asıl Yazarlar: Fujiwara, Yutaka, Hamada, Akinobu, Mizugaki, Hidenori, Aikawa, Hiroaki, Hata, Toshiyuki, Horinouchi, Hidehito, Kanda, Shintaro, Goto, Yasushi, Itahashi, Kota, Nokihara, Hiroshi, Yamamoto, Noboru, Ohe, Yuichiro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2016
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982581/
https://ncbi.nlm.nih.gov/pubmed/27270784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12983
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller